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ABSTRACT
Introduction We studied if motivational interviewing (MI) 
added to standard educational care (SEC) improves vascular 
health in adolescents with poorly controlled type 1 diabetes.
Research design and methods 47 adolescents with type 
1 diabetes of at least 2 years duration and hemoglobin A1c 
>75 mmol/mol (>9.0%) on two visits were randomized 
to MI+SEC or SEC. We also compared vascular health 
parameters of patients with type 1 diabetes at trial 
baseline with a group of healthy historical controls 
matched for age and body size.
Results 39 adolescents (20 MI+SEC) completed the 
vascular health study. At 12 months, parameter changes 
were not statistically significantly different between 
MI+SEC and SEC (carotid- femoral pulse wave velocity 
(cfPWV): mean difference 0.052 m/s (95% CI −0.395 to 
0.500, p=0.81); carotid- radial PWV (crPWV): 0.118 m/s 
(95% to 0.478 to 0.713, p=0.69), carotid intima- media 
thickness (IMT): 0.002 mm (95% CI −0.37 to 0.40, p=0.93), 
systolic blood pressure (BP) z- score: 0.495 (95% CI −0.099 
to 1.09, p=0.10). At baseline, duration of type 1 diabetes 
was associated with radial IMT (r=0.430, p=0.007) and 
cfPWV (r=0.373, p=0.018), and carotid, femoral and brachial 
IMT were correlated with continuous glucose monitoring 
(CGM) SD (r=0.440, p=0.017; r=0.377, p=0.048; r=0.387, 
p=0.038). There was an inverse association between CGM 
time- in- range (3.9–10.0 mmol/L) and crPWV (r=−0.476, 
p=0.022) changes. Systolic BP change was associated 
with body mass index change (r=0.374, p=0.019) and IMT 
change (r=0.461, p=0.016 for carotid IMT; r=0.498, p=0.010 
for femoral IMT). PWVs were higher and common carotid 
compliance lower among patients with type 1 diabetes 
at baseline compared with healthy controls, but no other 
differences were found.
Conclusion There was no effect of MI added to SEC on 
vascular health parameters. Although disease duration and 
glycemic control were associated with vascular health at 
baseline, there were only limited associations between 
glycemic control and vascular health parameter changes. 
Vascular health parameter changes were interrelated 
suggesting clustering of cardiovascular risk.
Trial registration number NCT02637154.
INTRODUCTION
Patients with type 1 diabetes (T1D) with 
optimal glycemic control suffer less from 
long- term vascular complications than those 
with poor control. Increased hemoglobin 
A1c (HbA1c) levels predict these complica-
tions. The development of diabetic compli-
cations seems to accelerate during puberty, 
and 5–7 years poor metabolic control during 
adolescence or young adulthood markedly 
increases the incidence of microvascular 
Significance of this study
What is already known about this subject?
 ► Poor glycemic control during adolescence predict 
overall long- term cardiovascular morbidity in indi-
viduals with type 1 diabetes.
 ► There is a lack of previous randomized controlled 
intervention trials to improve both glycemic con-
trol and vascular health in adolescents with type 1 
diabetes.
What are the new findings?
 ► The trial found no effect of motivational interviewing 
when added to standard care on adolescent glucose 
and vascular health parameters during a 12- month 
follow- up in adolescents with type 1 diabetes.
 ► Arterial stiffness was increased at baseline in ad-
olescents with type 1 diabetes compared with 
age- matched and body size- matched healthy 
adolescents.
 ► Vascular health parameters improved during follow- 
up in adolescents with type 1 diabetes with ad-
verse levels at the time of poor glycemic control at 
baseline.
 ► Longitudinal vascular health parameter changes 
were interrelated consistent with clustering of car-
diovascular risk in adolescents with type 1 diabetes.
How might these results change the focus of 
research or clinical practice?
 ► The study highlights the importance to monitor 
vascular health, in addition to glycemic control, 
and to introduce preventive measures focusing on 
cardiovascular risk among adolescents with type 1 
diabetes.
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or macrovascular complications during the following 
6–10 years.1–6 Optimal adherence to treatment during 
adolescence in turn has been reported to reduce the 
risk of microvascular complications, even if the benefi-
cial glucose control is lost later in life, implicating that 
puberty is an important time period for predicting the 
overall long- term morbidity in individuals with T1D.7–10
Insulin resistance and impaired metabolic control are 
common problems in adolescents with T1D despite signifi-
cant technological advancements including better tools for 
glycemic control. Treatment during puberty can be compli-
cated and treatment adherence often declines in transition 
to adolescence.11 At present, there is a lack of evidence 
based methods for clinicians treating adolescents with poor 
glycemic control to improve treatment adherence. Some 
small population- based studies report different interven-
tions including motivational interviewing (MI) provided 
by clinicians, ‘diabetes trainers’ or psychologists in vari-
able setting and with variable glycemic control outcomes 
ranging from substantial12 to no benefit.13 14 The clinical 
utility of MI added to a standard educational care (SEC) 
setting in the follow- up of adolescents with T1D is still 
unclear. A number of studies have also addressed associa-
tions between glycemic control and different parameters 
of vascular health in adolescents with T1D in both cross- 
sectional15 16 and longitudinal settings,17 18 but we are not 
aware of a previous randomized controlled intervention 
trial to improve both glycemic control and vascular health 
in youth.
Our hypothesis was that MI added to usual SEC would 
improve glycemic control resulting in better vascular 
health in adolescents with poorly controlled T1D. Our 
aim was thus to study the effect of MI on glycemic control 
and its associations with vascular health parameters in a 
randomized trial. We also compared adolescent poorly 
controlled T1D vascular health parameters at trial baseline 
with a group of healthy controls matched for age and body 
size.
METHODS
The randomized controlled Motivational Interview 
in Adolescents with poorly controlled type 1 Diabetes 
(MIAD) trial with participants allocated to MI+SEC 
(intervention) integrated to clinicians’ daily prac-
tice, as a part of normal clinical visit, or to usual SEC 
(control) was conducted at the Pediatric Diabetes Units 
of Helsinki University Hospital (Children’s Hospital and 
Jorvi Hospital) between October 2015 and August 2018. 
Inclusion criteria at enrollment were age between 12 and 
15.9 years, pubertal (Tanner) stage 2 or more and a diag-
nosis of T1D with at least 2 years duration and HbA1c 
>75 mmol/mol (>9.0 %) on two consecutive visits indi-
cating poor glycemic control. Exclusion criteria were 
celiac disease with poor control, diagnosis of psychiatric 
disease and other chronic disease requiring systemic 
glucocorticoid treatment.
Study subjects and protocol
Forty- seven Caucasian subjects (20 females) were 
recruited and entered the study. All subjects with T1D were 
attending ordinary government- run Finnish comprehen-
sive schools. Randomization was performed in permuted 
blocks of six patients with balanced numbers of interven-
tion and control subjects for each treating physician. Five 
subjects were not eligible for the cardiovascular assess-
ment as they were followed up in another center, one 
subject randomized to intervention was excluded prior 
to cardiovascular assessment at baseline due to technical 
problems, and two subjects, one randomized to control 
and one to intervention entered the study, but moved 
to another area and were lost for follow- up. Another 10 
subjects, 6 intervention and 4 controls, completed the 
study, but lack follow- up ultrasound data due to technical 
problems related to equipment brakedown and missing 
images. This manuscript reports data of all 39 subjects 
with T1D (20 MI+SEC) that participated in vascular 
health assessments. Patients were followed up by the 
treating physician every 3 months. HbA1c was assessed 
every 3 months. One subject (intervention) reported 
regular smoking. Vascular, body composition and addi-
tional fasting venous blood sampling were performed at 
baseline and 12 months. The investigator was blinded to 
all outcome variable assessments.
In addition to the randomized controlled MIAD study, 
we compared arterial structure and stiffness parameters 
of subjects with T1D at baseline with a historical healthy 
control group (case- control design). The healthy control 
group is described in online supplementary material. 
The proportion of females was slightly lower (15/40) 
compared with proportion of females among random-
ized patients with T1D (19/41). The historical control 
vascular health data have been reported previously.19
Motivational interviewing intervention
Physicians randomized (1:1) to employ MI were trained 
by a psychologist familiar with the method in a 2- day work-
shop. Rollnick’s textbook about MI in healthcare was used 
as a schoolbook for the method.20 Four important princi-
ples that form the basis of MI treatment are: (a) expres-
sion of empathy, (b) developing discrepancy between 
status quo and change, (c) rolling with resistance (as a 
natural phenomenon) and (d) supporting self- efficacy. 
The MI intervention was applied at each patient visit by 
incorporating the MI principles to usual SEC discussions, 
with a focus to improve adherence to glucose follow- up 
and insulin administration, as well as emphasizing 
personal benefits of improving glycemic control. SEC 
material provided to both groups included a test for carb 
counting and visual material on HbA1c targets, blood 
glucose targets, long- term diabetes complications, keto-
acidosis and hypoglycemia. Differences in subject SEC 
status or level was not assessed but their skills in carbohy-
drate counting was assessed with standard visual material 
by a diabetes nurse at baseline and 12- month study visits.
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Blood glucose monitoring
Continuous glucose monitoring (CGM; 6 days blinded 
continuous glucose monitoring, iPro, Medtronic or patients 
own CGM (if in use)) was performed at baseline and 12 
months in all subjects with T1D. CGM data were available 
for 11 individuals in the intervention (MI+SEC) and 18 in 
the control (SEC) group at baseline, and for 14 individuals 
in the intervention and 16 controls, at 12 months. Both 
baseline and 12- month CGM recordings were available in 
22 patients (9 intervention and 13 controls). Mean sensor 
glucose level, SD of sensor glucose values calculated coeffi-
cient of variation (CV, SD/mean) and time- in- range (TIR; 
defined as sensor glucose between 3.9 and 10.0 mmol/L) 
were analyzed from blinded CGM curves to define glycemic 
control and variability.21
Pulse wave velocity
All vascular health measures were obtained and analyzed 
with the investigator (TS) blinded to patient characteris-
tics and study group. Regional arterial pulse wave velocity 
(PWV) to assess arterial stiffness was measured using 
mechanosensors (Complior Analyse, Alam Medical, Saint- 
Quentin- Fallavier, France) at rest in supine position to 
simultaneously assess transit times between right carotid, 
femoral and radial arteries for central or aortic (right 
carotid- femoral) and peripheral or brachial (right carotid- 
radial) PWVs. The direct distance between recording sites 
were measured using a tape measure to the nearest 0.1 cm. 
The distance from the jugulum to the carotid pulse was 
subtracted from the direct carotid- radial distance, and the 
carotid- femoral distance was multiplied by 0.8. Two record-
ings were obtained with a third recording performed in the 
setting of a >0.5 m/s (10%) difference between measure-
ments. In the setting of more than two measurements, the 
results with the lowest tolerance values were used in anal-
yses. The mean of at least two measurements was used in 
final analyses. The CV for repeat measurements were 3.8% 
for carotid- femoral PWV and 2.8% for carotid- radial PWV 
(n=80, including baseline and follow- up assessments). 
Historical controls were assessed (by TS) during identical 
conditions and criteria for distance assessments using the 
SphygmoCor system (AtCor Medical, Itasca, Illinois, USA) 
to assess transit time. SphygmoCor and Complior Analyse 
has previously been shown to provide equivalent PWV 
results and without bias.22
Vascular ultrasound
Very high- resolution ultrasound images were obtained 
(TS) with Vevo 770 and, due to breakdown of the 
equipment beyond repair, with Vevo MD (VisualSonics, 
Toronto, Canada) for the last 10 baseline assessments 
and for all but 3 follow- up assessments. The Vevo 770 
was equipped with mechanical RMV- 710B, RMV-712 
and RMV-708 transducers with center frequencies 25, 
35 and 55MHz, respectively. The Vevo MD was equipped 
with electronic UHF22, UHF48 and UHF70 transducers, 
with 15, 30 and 50MHz center frequencies, respectively. 
Imaging was performed and measurements obtained 
as described.23 Ultrasound methods are described in 
online supplementary materials. Historical controls were 
assessed by TS with the Vevo 770 system using identical 
imaging protocols including transducers, anatomical 
locations, cardiac cycle and offline measurement criteria.
Anthropometrics and body composition
Subject height was assessed with an electronic stadiometer 
(Seca & co. kg, Hamburg, Germany) and measured to the 
nearest 0.1 cm. Weight was assessed using an electronic scale 
(Seca 770, Seca & co. kg) to the nearest 0.1 kg. Hip and 
waist circumference were measured with a tape measure 
to the nearest 0.5 cm. Z- scores for child height and body 
mass index (BMI) were derived using the recent Finnish 
reference data.24 Overweight and obesity was defined using 
International Obesity Task Force (IOTF) criteria.25
Body composition was assessed with dual- energy absorp-
tiometry (DXA, Hologic Discovery A, Waltham, Massachu-
setts, USA) at 0 and 12 months. For historical controls, 
lean body mass (LBM) was derived using the previously 
DXA- based validated formula26 and fat mass was calcu-
lated as LBM subtracted from total body weight. Body fat 
percentage was calculated as fat mass divided by total body 
weight.
Blood pressure
Blood pressure (BP) was assessed according to US National 
High Blood Pressure Education Program (NHBPEP) 4th 
report guidelines using three repeat oscillometric measure-
ments (Dinamap ProCare 200, GE) at rest in sitting posi-
tion after 15 min rest. A difference of <5 mm Hg between 
measures was deemed appropriate. The mean of the two 
lowest readings were used in analyses. Systolic BP and 
diastolic BP z- scores were generated using the 4th report 
reference.
Blood work and analyses
HbA1c levels were measured during each visit from 
fingertip samples (Afinion). All other blood samples 
were taken by a trained laboratory technician after 
fasting. Plasma glucose was determined using enzy-
matic hexokinase assay (Roche Diagnostics, Basel, 
Switzerland), low- density lipoprotein, high- density lipo-
protein, triglycerides and total cholesterol were deter-
mined using enzymatic assays (Abbott, Illinois, USA). 
1.5- Anhydroglucitol (1.5- AG) was analyzed from serum 
samples according to assay brochure using a commercial 
kit (GlycoMark, New York, USA). High- sensitivity C reac-
tive protein (hs- CRP) was determined immunochem-
ically. Microalbuminuria was assessed from spot urine 
samples by determining albumin- to- creatinine ratio. 
Urine albumin was determined immunochemically and 
urine creatinine enzymatically. Microalbuminuria was 
defined as present when albumin- to- creatinine ratio was 
>3.5 mg/mmol in spot urine sample.
Data analyses
Data are presented as mean and SD or as count and 
percentage. All continuous variables were assessed for 
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normal distributions graphically using histograms as well as 
with the Shapiro- Wilk test.
Predefined primary outcome of the MIAD study was 
change in HbA1c and glycemic variability between base-
line and 12 months, and glycemic variables were included 
as background variables to study associations with labo-
ratory measures of cardiovascular risk and vascular 
health parameters in the present manuscript. Predefined 
secondary vascular health outcomes were change in arte-
rial IMT, PWV, blood pressure and inflammatory marker 
hs- CRP between baseline and 12 months. Heart rate, 
anthropometrics, and body composition parameters 
were included as confounders in the analyses.
Predefined power calculations for the MIAD were based 
on the probability of a significant 1% absolute difference 
between HbA1c change from baseline to 12 months between 
intervention (MI+SEC) and control (SEC). With an HbA1c 
SD of 1.24, power of 80% and alpha 0.05, a maximum 
dropout rate of 8%, a total of 50 patients with T1D would 
have been needed for the study. Predefined power calcu-
lations for the case- control study part were based on the 
probability of a 10% absolute difference between patients 
with T1D at baseline and healthy controls. With an IMT SD 
of 0.07 and PWV SD of 1.0, power of 80% and alpha 0.05, a 
total of 40 patients with T1D and healthy 40 controls would 
have been needed for the study.
Associations between variables obtained at baseline were 
initially analyzed. Patients with T1D were compared with 
historical controls, and T1D patient z- scores with a healthy 
reference population mean, using simple Student’s t- test. 
Associations between vascular health parameters and back-
ground variables were then explored with bivariate Pear-
son’s correlations including both patients with T1D and 
historical controls in the analyses. Associations between 
glycemic variables and vascular health variables were 
explored similarly among patients with T1D.
Main outcome measures related to intervention were 
assessed comparing mean differences (and 95% CIs 
for mean difference) between intervention and control 
groups at follow- up based on univariate analysis of cova-
riance (General Linear Model (GLM)) models entering 
treatment as fixed factor and baseline as covariate. Asso-
ciations between baseline values and absolute change in 
values between baseline and 12 months, as well as asso-
ciations between absolute change between glucose and 
vascular health parameters from baseline to 12 months 
was explored with scatter plots and Pearson’s correla-
tions. Bonferroni corrections were not made and p<0.05 
was considered to be statistically significant. Analyses were 
performed with SPSS Statistics V.25.
RESULTS
Vascular health at baseline and comparison with historical 
controls
No statistically significant differences between patients 
with T1D and historical controls or between patients with 
T1D between MI+SEC and SEC groups were found in sex, 
age, body size or body composition (table 1). Central and 
peripheral PWV were higher and local common carotid 
compliance was lower among patients with T1D compared 
with historical controls (table 2). There were no statisti-
cally significant difference in arterial wall layer thickness or 
lumen diameter between patients with T1D and historical 
controls (table 2). BMI z- score was higher and diastolic BP 
z- score lower among patients with T1D compared with the 
reference population (tables 1 and 2).
At baseline, age was positively associated with femoral 
artery intima- media thickness (IMT) and intima- media- 
adventitia thickness (IMAT), and LBM positively asso-
ciated with peripheral artery IMT and IMAT (online 
supplementary table 1). Systolic BP z- score was associated 
positively with PWV, local carotid artery compliance and 
stiffness, as well as with carotid and radial artery IMT. 
There were no significant associations between different 
measures of adiposity (BMI z- score, waist- to- hip ratio, 
body fat percentage) or sex and vascular health parame-
ters (online supplementary table 1). Duration of T1D was 
positively associated with radial IMT and carotid- femoral 
PWV (online supplementary table 2, figure 1A), and 
these associations remained statistically significant when 
adjusting for age, systolic BP z- score and BMI z- score with 
multiple linear regression analyses. Carotid, femoral and 
brachial IMT was correlated with CGM SD (figure 1B), 
and carotid IMT in addition with CGM CV. No significant 
associations between BP or PWV, and glycemic control 
variables were found. Similarly, hs- CRP was correlated 
with systolic BP z- score (online supplementary table 3). 
There were no consistent associations between lipids and 
vascular health parameters (online supplementary table 
3).
Change in glucose and vascular health parameters
No statistically significant differences between the 
MI+SEC and SEC groups were found in HbA1c, 1.5- AG, 
body size, body composition, blood pressure, arterial 
structure or stiffness parameters including arterial IMTs 
and PWVs, fasting blood lipids or hs- CRP levels from 
baseline to 12 months when adjusting for baseline levels 
(table 3).
Associations between changes in different parameters 
of glycemic control including HbA1c, 1.5- AG and CGM 
recordings (mean glucose levels, SD, CV and TIR), and 
changes in vascular health parameters (PWVs, IMT, BPs) 
were found not statistically significant (table 4), except 
for a statistically significant inverse (negative) associ-
ation between change in TIR and carotid- radial PWV 
(r=−0.476, p=0.022, figure 1E).
There were significant associations between longitu-
dinal changes in vascular health parameters. Change in 
systolic BP was correlated with change in BMI (r=0.374, 
p=0.019, figure 1D) and change in IMT (r=0.461, p=0.016 
for carotid IMT; r=0.498, p=0.010 for femoral IMT; 
figure 1C). Change in hs- CRP was positively associated 
with diastolic BP change, but not with systolic BP change, 
and nearly significant trends between change in hs- CRP 
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Table 1 Characteristics of study subjects at baseline
Variable T1D intervention T1D control T1D all Historical controls
N 20 21 41 40
Male sex (N) 12 (60%) 10 (48%) 22 (54%) 25 (63%)
Age (years) 14.6 (0.9) 14.6 (0.8) 14.6 (0.8) 14.7 (1.0)
Duration of diabetes (years) 8.1 (3.6) 7.9 (3.8) 8.1 (3.7)
Continuous subcutaneous insulin infusion 13 14 27
Insulin multiple daily injections 7 7 14
Smoking (n) 1 (5%) 0 1 (2%) 0
Height (cm) 167.8 (7.2) 167.4 (6.2) 167.6 (6.6) 165.7 (10)
Weight (kg) 65.1 (12.0) 61.7 (13.4) 63.3 (12.7) 58.6 (13.0)
BMI (kg/m2) 23.1 (3.7) 22.0 (4.4) 22.5 (4.1) 21.2 (3.5)
BMI z- score 0.76 (0.88) 0.39 (1.02) 0.57 (0.96)*** 0.22 (0.91)
Waist (cm) 78.7 (9.3) 74.6 (10.4) 76.6 (10.0) NA
Waist- to- hip ratio 0.84 (0.06) 0.81 (0.05) 0.83 (0.05) NA
Waist- to- height ratio 0.47 (0.05) 0.45 (0.06) 0.46 (0.06) NA
Lean body mass (kg)† 40.7 (7.1) 38.7 (6.1) 39.7 (6.6) 42.5 (8.9)
Fat mass (kg)† 17.7 (7.0) 17.0 (8.9) 17.3 (7.9) 16.2 (5.8)
Body fat (%)† 28.9 (7.8) 28.4 (9.1) 28.6 (8.3) 27.6 (5.3)
Body surface area (m2) 1.73 (0.18) 1.69 (0.19) 1.71 (0.19) 1.64 (0.22)
Tanner stage
  M2/P3 0 1 1 NA
  M4/P3- P4 0 3 3
  M5/P5 8 7 15
  G2P2 0 1 1
  G3P2- P3 5 2 7
  G4P3- P4 5 4 9
  G5P5 1 1 2
  Missing data 1 2 3
Laboratory data
  HbA1c (mmol/mol) 87.5 (13.7) 84.3 (11.9) 85.9 (12.7)
  HbA1c (%) 10.2 (1.2) 9.9 (1.1) 10.0 (1.2)
  1,5- Anhydroglucitol (μg/mL) 2.16 (1.16) 2.37 (1.16) 2.26 (1.32)
Continuous glucose monitoring (CGM)‡
  Mean (mmol/L) 12.2 (2.4) 11.4 (2.2) 11.7 (2.3)
  SD (mmol/L) 4.8 (1.3) 5.0 (1.4) 4.9 (1.4)
  CV (%) 39.2 (9.0) 45.1 (13.3) 42.9 (12.1)
  Time- in- range (%) 33 (21) 36 (11) 35 (16)
Total cholesterol (mmol/L) 4.46 (0.75) 4.83 (1.12) 4.65 (0.96)
HDL cholesterol (mmol/L) 1.53 (0.35) 1.71 (0.45) 1.62 (0.41)
LDL cholesterol (mmol/L) 2.77 (0.73) 2.95 (1.00) 2.86 (0.87)
Triglycerides (mmol/L) 1.15 (0.62) 1.11 (0.99) 1.13 (0.82)
Alanine aminotransferase (U/L) 14 (5) 20 (14) 17 (11)
Gamma- glutamyltransferase (U/L) 15 (7) 17 (12) 16 (9)
hs- CRP (mg/L) 0.54 (0.10–9.64) 0.90 (0.10–11.59) 0.56 (0.10–11.59)
Microalbuminuria (present)§ 2 2 4
Data are presented as mean (SD) or as count and percentage. hs- CRP is presented as median (range).
***p<0.001 between historical controls and T1D All (and BMI z- score different from population mean for T1D All), other comparisons between historical controls and T1D all as well as 
T1D controls vs T1D intervention were statistically non- significant (p>0.05).
†Calculated body composition data based on formula is reported for historical controls.26
‡CGM data available for 18 controls with T1D and 11 T1D interventions at baseline. CGM mean is mean glucose, CGM SD is SD of glucose variability, CGM CV is coefficient of 
variation (SD/mean) and CGM time- in- range is proportion of time glucose between 3.9 and 10.0 mmol/L during continuous glucose monitoring.
§Microalbuminuria data at baseline available in 37/41 patients with T1D; microalbuminuria was defined as present when albumin- to- creatinine ratio was >3.5 mg/mmol in spot urine.
BMI, body mass index ; HbA1c, hemoglobin A1c; HDL, high- density lipoprotein; hs- CRP, high- sensitivity C reactive protein; LDL, low- density lipoprotein; NA, not assessed; T1D, type 
1 diabetes.
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and change carotid- femoral PWV and carotid- radial 
PWV was also observed (table 4). There was a negative 
correlation between systolic BP at baseline and change 
(r=−0.452, p=0.004, online supplementary figure 1). 
There was a similar correlation between PWV at baseline 
and change (r=−0.685, p<0.001 for carotid- femoral PWV; 
r=−0.765, p<0.001 for carotid- radial PWV, online supple-
mentary figure 2).
DISCUSSION
This MIAD study was unable to demonstrate a beneficial 
effect of MI, when added to SEC in the outpatient clinic, 
on vascular health. Longitudinal changes in vascular 
health parameters including measures of adiposity (BMI 
z- score), BP, arterial wall layer thickness (IMT) and stiff-
ness (PWV) were interrelated in the study and consistent 
with longitudinal clustering of adverse vascular health 
parameters in the adolescent population with T1D. 
Duration of T1D and different measures of glycemic 
control were positively associated with arterial layer thick-
ness and central aortic PWV at baseline. However, longi-
tudinal changes in measures of glycemic control were not 
consistently associated with changes in vascular health 
parameters apart from an isolated finding of a negative 
association between TIR and peripheral vascular stiffness 
(carotid- radial PWV). Improvements in vascular health 
parameters were, nevertheless, seen among patients with 
T1D with adverse levels at the time of poor glycemic 
control at study enrollment.
The larger randomized controlled Flexible Lifestyles 
Empowering Change (FLEX) study reported, similar 
to our study, no effect of a modified MI intervention 
compared with usual care only on HbA1c at 18 months 
among adolescent with T1D.27 Furthermore, this 
study found no effect of MI on 1.5- AG—a short term 
biomarker of glycemic variability and excursions.28 The 
Table 2 Vascular health characteristics of study subjects at baseline
Variable T1D intervention T1D control T1D all Historical controls
N 20 21 41 40
Blood pressure (BP)
Systolic BP (mm Hg) 114 (10) 115 (10) 115 (10) NA
Systolic BP z- score 0.17 (0.93) 0.32 (0.89) 0.25 (0.90)
Diastolic BP (mm Hg) 59 (4) 57 (7) 58 (6)
Diastolic BP z- score −0.50 (0.39) −0.72 (0.61) −0.61 (0.52)***
Pulse wave velocity (PWV)
  Carotid- femoral PWV (m/s) 5.7 (0.9) 5.4 (0.8) 5.6 (0.8)*** 4.0 (0.8)
  Carotid- radial PWV (m/s) 7.4 (1.4) 7.2 (0.8) 7.3 (1.2)*** 6.3 (1.1)
Common carotid artery
  Intima- media thickness (mm) 0.41 (0.05) 0.41 (0.04) 0.41 (0.04) 0.42 (0.06)
  Lumen diameter (mm) 5.23 (0.38) 5.09 (0.37) 5.16 (0.38)* 5.39 (0.46)
  Compliance (%/10 mm Hg) 2.38 (0.49) 2.51 (0.38) 2.45 (0.43)*** 3.30 (0.76)
  Stiffness (no unit) 4.58 (1.02) 4.24 (0.70) 4.40 (0.87) 4.21 (1.09)
Radial artery
  Intima- media thickness (mm) 0.14 (0.02) 0.14 (0.03) 0.14 (0.02) 0.14 (0.02)
  Intima- media- adventitia thickness (mm) 0.21 (0.03) 0.21 (0.04) 0.21 (0.03) 0.22 (0.03)
  Lumen diameter (mm) 1.76 (0.31) 1.64 (0.23) 1.70 (0.28) 1.78 (0.30)
Brachial artery
  Intima- media thickness (mm) 0.14 (0.02) 0.14 (0.02) 0.14 (0.02) 0.13 (0.02)
  Intima- media- adventitia thickness (mm) 0.25 (0.04) 0.26 (0.05) 0.26 (0.04) 0.24 (0.04)
  Lumen diameter (mm) 2.98 (0.47) 3.00 (0.32) 2.99 (0.39) 2.98 (0.54)
Femoral artery
  Intima- media thickness (mm) 0.24 (0.04) 0.26 (0.06) 0.25 (0.05) 0.26 (0.05)
  Intima- media- adventitia thickness (mm) 0.46 (0.07) 0.50 (0.08) 0.48 (0.08) 0.49 (0.08)
  Lumen diameter (mm) 6.23 (0.68) 6.26 (0.74) 6.24 (0.70) 6.69 (1.13)
Data are presented as mean (SD) or as count.
*P<0.05, ***p<0.001 between T1D all and historical controls, other comparisons between historical controls and T1D all as well as between 
T1D intervention vs T1D control were statistically non- significant (p>0.05).
NA, not assessed; T1D, type 1 diabetes.
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main MIAD study outcome variable, change in HbA1c as 
well as changes in CGM will be presented in more detail 
in another manuscript (Tuomaala et al, unpublished data 
2020). Presuming a positive association between glycemic 
control and vascular health parameters, it is not surprising 
that we were unable to demonstrate a statistically signif-
icant difference between SEC and MI+SEC groups in 
vascular health parameters in the present MIAD study. 
Although the MI intervention was developed >30 years 
ago, still the evidence of its benefits in adolescent popu-
lations seems somewhat limited.29 On the other hand, 12 
months is a relatively short time period to assess the effect 
of MI on long- term glycemic control and vascular health 
as change in subject’s behavior and vascular health may 
take much longer, especially when assessing arterial wall 
structures among adolescents with T1D.30
We were unable to find a randomized controlled trial 
addressing the potential effect of MI, educational or 
psychosocial program on vascular health in adolescent 
patients with T1D with poor glycemic control. Previous 
cross- sectional and longitudinal studies show increased 
PWV among patients with T1D compared with healthy 
controls,16 interrelations between diabetes duration and 
IMT,31 as well as increasing BMI z- score and progression 
of carotid IMT,18 32 and increase of BP with age and 
progression of PWV.17 We found no difference in arterial 
IMTs between patients with T1D and healthy controls, 
which is in line with earlier studies reporting differences 
confined to the carotid bulb IMT only but not in other 
carotid artery segments.33 Presence, clustering and wors-
ening of CV risk factors have been found to be associ-
ated with an increased central PWV among adolescent 
patients with T1D.34 Furthermore, previous Swedish 
registry data show that coronary artery disease is nine 
times more common among patients diagnosed with T1D 
early in life compared with age- matched controls.35 The 
adverse effects of longitudinal cumulative cardiovascular 
risk exposure from adolescence to adulthood on vascular 
health is well established in non- diabetic populations.36 
Our results support these previous findings, although we 
were unable to confirm associations between declining 
glucose control and increased central PWV. However, 
Gordin et al showed an acute increase in right arm arte-
rial stiffness, but not in central aortic arterial stiffness, 
during an acute hyperglycemia clamp study among males 
aged 18–40 years with T1D and relatively good glycemic 
control (HbA1c 7.9%±0.9%).37 Our results showing an 
association between an improvement in CGM TIR and 
a decrease in right arm PWV is in line with this and 
suggests that peripheral arterial stiffness might be more 
sensitive to excessive or unstable blood glucose variations 
compared with central aortic stiffness.
This study is limited due to a small sample size and 
short follow- up. The study inclusion criteria of poor 
glycemic control was simple and did not include in- depth 
motivational or other psychological nor diabetes self- 
management profiling. In addition, the intervention 
was focused on improving glycemic control, and did not 
directly address cardiovascular risk or vascular health. 
Although retention of patients with T1D was good, we 
still acknowledge some missing ultrasound imaging and 
CGM data. Measures of vascular stiffness (PWV) were, 
however, complete and we were able to include a histor-
ical healthy control group matched for age and body 
size as well. Endothelial function assessments using flow- 
mediated dilatation (FMD) or peripheral reactive hyper-
emia (EndoPat) were not feasible due to known high 
technical measurement variance in longitudinal study 
settings encompassing several months requiring large 
sample sizes for adequate study power.38 39 We, however, 
included a representative sample and applied recently 
validated novel biomicroscopy technology including 
multiple arterial site assessments and providing more 
detailed information regarding the arterial wall structure.
In conclusion, we observed no statistically significant 
benefit of MI, when added to SEC, on vascular health 
among adolescents with T1D with poor glycemic control. 
Although we found significant associations between T1D 
duration, glycemic control and vascular health parame-
ters at baseline, we were able to see only limited associa-
tions between changes in glycemic control and changes 
in vascular health parameters during follow- up. Adverse 
Figure 1 Type 1 diabetes (T1D) duration associated with 
radial artery intima- media thickness (IMT) at baseline (A), SD 
of mean glucose per continuous glucose monitoring (CGM) 
associated with common carotid artery IMT at baseline (B), 
systolic blood pressure change associated with common 
carotid artery IMT change (C), body mass index (BMI) change 
positively associated with systolic blood pressure change 
(D), glucose time- in- range (TIR) change per CGM change 
negatively associated with carotid- radial pulse wave velocity 
(PWV) change (E). Closed circles denote T1D intervention 
and open circles denote T1D controls.
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Table 3 Absolute change from baseline to 12- month follow- up, mean difference and CIs of mean difference for 
anthropometric, laboratory and vascular outcomes of the intervention and control groups
Variable
T1D intervention
change
T1D
control change
Mean 
difference 95% CI P value
N 19 20
Height (cm) 1.8 (6.8) 5.5 (6.3) −3.66 −7.592 to 0.273 0.067
Weight (kg) 4.9 (7.7) 6.6 (8.1) −1.18 −6.206 to 3.838 0.635
BMI (kg/m2) 1.2 (3.0) 0.9 (2.4) 0.55 −1.179 to 2.289 0.520
BMI z- score 0.13 (0.73) 0.12 (0.64) 0.10 −0.32 to 0.53 0.633
Waist (cm) 3.3 (10.7) 2.6 (6.7) 2.26 −3.365 to 7.896 0.420
Waist- to- hip ratio 0.01 (0.13) −0.01 (0.04) 0.055 −0.006 to 0.116 0.078
Waist- to- height ratio 0.01 (0.07) 0.006 (0.04) 0.025 −0.010 to 0.059 0.156
Lean body mass (kg) 2.6 (5.8) 5.4 (5.2) −2.6 −6.18 to 1.04 0.157
Fat mass (kg) 1.8 (3.2) 1.6 (1.4) 0.23 −1.41 to 1.87 0.776
Body fat (%) 0.016 (0.025) 0.013 (0.012) 0 −0.13 to 0.13 0.994
HbA1c (mmol/mol) −3.5 (16.8) 0.9 (18.8) −1.1 −10.8 to 8.5 0.817
HbA1c (%) −0.34 (1.51) 0.07 (1.73) −0.12 −1.00 to 0.76 0.792
1,5- Anhydroglucitol (μg/mL) 0.23 (1.50) −0.37 (1.47) 0.38 −0.46 to 1.22 0.360
Total cholesterol (mmol/L) −0.04 (0.66) −0.36 (0.87) 0.12 −0.38 to 0.62 0.635
HDL cholesterol (mmol/L) −0.14 (0.23) −0.31 (0.28) 0.09 −0.06 to 0.24 0.227
LDL cholesterol (mmol/L) 0.02 (0.60) −0.25 (0.71) 0.12 0.28 to 0.53 0.549
Triglycerides (mmol/L) 0.29 (0.90) 0.33 (0.86) −0.04 −0.65 to 0.57 0.896
hs- CRP (mg/L) 0.47 (2.29) 1.33 (2.34) −0.85 −2.41 to 0.71 0.273
Systolic BP (mm Hg) 1.7 (9.1) −2.6 (12.3) 3.76 −2.433 to 9.963 0.226
Systolic BP z- score 0.003 (0.88) −0.572 (1.25) 0.495 −0.099 to 1.09 0.100
Diastolic BP (mm Hg) −0.4 (5.6) 0.2 (6.2) 1.35 −2.188 to 4.892 0.444
Diastolic BP z- score −0.100 −0.136 0.203 −0.117 to 0.523 0.207
Pulse pressure 2.1 (7.9) −2.7 (12.0) 2.34 −3.368 to 8.058 0.411
Carotid- femoral PWV (m/s) 0.11 (1.00) 0.32 (0.83) 0.052 −0.395 to 0.500 0.813
Carotid- radial PWV (m/s) 0.28 (1.66) 0.44 (1.12) 0.118 −0.478 to 0.713 0.691
Common carotid artery
  Intima- media thickness (mm) −0.008 (0.044) 0.008 (0.069) 0.002 −0.37 to 0.40 0.933
  Lumen diameter (mm) 0.082 (0.386) −0.123 (0.374) 0.227 −0.38 to 0.492 0.090
  Compliance (%/10 mm Hg) 0.46 (0.61) 0.44 (0.52) −0.031 −0.41 to 0.35 0.867
  Stiffness (no unit) 0.48 (1.32) 0.62 (0.82) −0.069 −0.79 to 0.65 0.846
Radial artery
  Intima- media thickness (mm) −0.011 (0.032) 0.005 (0.020) −0.013 −0.033 to 0.006 0.158
  intima- media- adventitia thickness (mm) −0.014 (0.038) 0.009 (0.026) −0.020 −0.43 to 0.004 0.093
  Lumen diameter (mm) 0.195 (0.384) 0.069 (0.200) 0.142 −0.054 to 0.339 0.148
Brachial artery
  Intima- media thickness (mm) −0.008 (0.027) −0.001 (0.023) −0.002 −0.018 to 0.014 0.815
  intima- media- adventitia thickness (mm) −0.014 (0.037) 0.008 (0.044) −0.014 −0.035 to 0.006 0.159
  Lumen diameter (mm) 0.170 (0.272) −0.037 (0.437) 0.207 −0.071 to 0.485 0.137
Femoral artery
  Intima- media thickness (mm) 0.031 (0.082) 0.015 (0.038) 0.012 −0.035 to 0.059 0.590
  Intima- media- adventitia thickness (mm) 0.054 (0.159) 0.038 (0.067) 0.004 −0.073 to 0.082 0.905
  Lumen diameter (mm) 0.207 (0.263) −0.128 (0.845) 0.330 −0.275 to 0.935 0.267
Mean differences between intervention and control group at follow- up based on univariate analysis of covariance (GLM) models are adjusted for 
baseline values. No statistically significant effect of intervention on anthropometrics, body composition or cardiovascular parameters was found.
BMI, body mass index; BP, blood pressure; GLM, General Linear Model; HbA1c, hemoglobin A1c; HDL, high- density lipoprotein; hs- CRP, high- 
sensitivity C reactive protein; LDL, low- density lipoprotein; PWV, pulse wave velocity; T1D, type 1 diabetes.
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longitudinal changes in vascular health parameters were, 
however, interrelated suggesting clustering of cardio-
vascular risk. The study highlights the importance to 
monitor vascular health, in addition to glycemic control, 
and to introduce preventive measures focusing on 
cardiovascular risk among adolescents with T1D in the 
outpatient clinic.
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